• Record quarterly cash receipts of $22.4M
• FY25 positive operating cashflow of $5.8M, a $12.9M improvement on the prior year
• Record annual receipts of $50.9M, up 16% on the prior year

Alcidion Group Limited (ASX:ALC) has released its Appendix 4C and Quarterly Activities Report for the quarter ended 30 June 2025 (Q4 FY25). The company reported a very strong quarter, with positive operating cashflow of $7.4M, the highest quarterly positive cashflow in the company's history. This resulted in a full year positive operating cashflow of $5.8M, also a record result for the business. Alcidion generated Q4 new sales of $6.7M, of which approximately 73% is recurring product revenue and 27% is non-recurring services revenue. Cash receipts from customers in Q4 were $22.4M, which includes the payment from North Cumbria Integrated Care NHS Trust (NCIC) for the upfront capital licence component. For the full year, Alcidion recorded record annual receipts of $50.9M, up 16% on the prior year. The company also signed several expansions to existing contracts in Q4, notably with Hume, NALHN and NT Health, further demonstrating the value proposition of the Miya Precision platform. Alcidion reconfirms its recently upgraded guidance to deliver FY25 EBITDA exceeding $4.5M.

Alcidion reconfirms guidance for FY25 EBITDA to exceed $4.5M.

Following several material new contracts in FY25, Alcidion continues to progress new and expansion contract opportunities with increasing momentum. The company will provide an update on FY26 contracted revenue and financial guidance as part of the full year FY25 results.